ProMIS Neurosciences Inc.

Contributing Author

Recent Articles by ProMIS Neurosciences Inc.

Sep-01	ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September PMN GlobeNewswire
Aug-13	ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights PMN GlobeNewswire
Aug-03	ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 PMN GlobeNewswire
Jul-28	ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial PMN +23.89% GlobeNewswire
Jul-27	ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease PMN GlobeNewswire
Jul-14	ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 PMN +6.72% GlobeNewswire
May-28	ProMIS Neurosciences to Participate in Upcoming Conferences in June PMN GlobeNewswire
May-12	ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights PMN GlobeNewswire
Mar-25	ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights PMN -9.06% GlobeNewswire
Mar-18	ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD) PMN -13.04% GlobeNewswire
Feb-04	ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PMN PMN -16.29% GlobeNewswire
Jan-30	ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing PMN +17.95% GlobeNewswire
Dec-18	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease PMN -5.61% GlobeNewswire
Dec-18	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease PMN -5.61% GlobeNewswire
Dec-10	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk PMN +12.00% GlobeNewswire
Dec-01	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 PMN GlobeNewswire
Dec-01	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference PMN GlobeNewswire
Nov-24	ProMIS Neurosciences Announces Reverse Stock Split PMN -22.36% GlobeNewswire
Nov-12	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights PMN GlobeNewswire
Nov-03	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference PMN GlobeNewswire
Oct-22	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group PMN GlobeNewswire
Sep-03	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 PMN -14.76% GlobeNewswire
Aug-13	ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights PMN GlobeNewswire
Jul-29	ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference PMN -6.67% GlobeNewswire
Jul-28	ProMIS Neurosciences Announces Private Placement Financing PMN -8.76% GlobeNewswire
Jul-22	ProMIS Neurosciences Announces Private Placement Financing PMN -26.79% GlobeNewswire
Jul-22	ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules PMN -26.79% GlobeNewswire
Jul-21	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease PMN +154.49% GlobeNewswire
Jul-21	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease PMN +154.49% GlobeNewswire
Jun-17	ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference PMN GlobeNewswire
May-12	ProMIS Neurosciences Announces First Quarter 2025 Financial Results PMN GlobeNewswire

ProMIS Neurosciences Inc.

Recent Articles by ProMIS Neurosciences Inc.

Upgrade your Finviz experience